Cantitate/Preț
Produs
Total produse
Vezi coșul
Introduction to Market Access for Pharmaceuticals de Mondher Toumi

Introduction to Market Access for Pharmaceuticals

Editat de Mondher Toumi
en Limba Engleză Paperback – 4 ian 2017
Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers’ needs, the drug will fail to reach its intended market value. Introduction to Market Access for Pharmaceuticals is based on an accredited course in this area, taken from the European Market Access University Diploma (EMAUD), and is affiliated with Aix Marseille University.
Key Features:
  • The first guide to market access for pharmaceuticals based on tested teaching materials
  • Addresses both pharmaceutical and vaccine products
  • Includes case studies and scenarios
  • Covers market access consdierations for Western Europe, the USA, Japan and China
  • Explains the impact the changing healthcare market will have on your product
    • Citește tot Restrânge

    Preț: 64950 lei

    Preț vechi: 87692 lei
    -26% Nou

    Puncte Express: 974
    Preț estimativ în valută:
    12431€ • 12957$ • 10349£

    Carte tipărită la comandă

    Livrare economică 04-18 ianuarie 25
    Livrare express 03-07 decembrie pentru 17991 lei

     Adaugă în coș

    Wish list
    Gift list
    Am citit!
    Adaugă în listă
    Preluare comenzi: 021 569.72.76

    Specificații

    ISBN-13: 9781138032187
    ISBN-10: 1138032182
    Pagini: 204
    Ilustrații: 40 Tables, black and white; 25 Illustrations, black and white
    Dimensiuni: 210 x 280 x 13 mm
    Greutate: 0.48 kg
    Ediția:1
    Editura: CRC Press
    Colecția CRC Press
    Locul publicării:Boca Raton, United States

    Cuprins

    Chapter 1: Health as a Good
    Chapter 2: Decision-Making in Public Health
    Chapter 3: Definition and Concepts
    Chapter 4: HTA Decision Analysis framework
    Chapter 5: Early HTA Advice
    Chapter 6: Overview of Market Access Agreements
    Chapter 7: External Reference Pricing
    Chapter 8: Gap between Payers and Regulators
    Chapter 9: Early Access Programs
    Chapter 10: Market Access of Orphan Drugs
    Chapter 11: Market Access of Vaccines in Developed Countries
    Chapter 12: France
    Chapter 13: Germany
    Chapter 14: Italy
    Chapter 15: Spain
    Chapter 16: Sweden
    Chapter 17: United Kingdom
    Chapter 18: The United States
    Chapter 19: Japan
    Chapter 20: China

    Notă biografică

    Mondher Toumi is M.D. by training, M.Sc. in Biostatistics, and in Biological Sciences (option pharmacology) and Ph.D. in Economic Sciences. Mondher Toumi is Professor of Public Health at Aix-Marseille University. After working for 12 years as Research Manager in the department of pharmacology at the University of Marseille, he joined the Public Health Department in 1993. In 1995 he embraces a carrier in the pharmaceutical industry for 13 years. Toumi was appointed Global Vice President at Lundbeck A/S in charge of health economics, outcome research, pricing, market access, epidemiology, risk management, governmental affairs and competitive intelligence. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making. In February 2009 he was appointed Professor at Lyon I University in the Department of Decision Sciences and Health Policies. The same year, he was appointed Director of the Chair of Public Health and Market Access. He launched the first European University Diploma of Market Access (EMAUD) an international course already followed by almost 350 students. Additionally, he recently created the Market Access Society to promote education, research and scientific activities at the interface of market access, HTA, public health and health economic assessment. He is editor in Chief of the Journal of Market Access and Health Policy (JMAHP) which was just granted PubMed indexation. Toumi is also visiting Professor at Beijing University (Third Hospital). He is a recognized expert in health economics and an authority on market access and risk management. He has more than 250 scientific publications and communications, and has contributed to several books.

    Descriere

    Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers’ needs, the drug will fail to reach its intended market value. Introduction to Market Access for Pharmaceuticals is based on an accredited course in this area, taken from the European Market Access University Diploma (EMAUD), and is affiliated with Aix Marseille University.